logo
Twitter
Discord
Email
logo
logo
Aurinia Pharmaceuticals Inc.NASDAQ - AUPH
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-07
2024-06-30 10-Q2024-06-302024-08-01
2024-03-31 10-Q2024-03-312024-05-02
2023-12-31 10-K2023-12-312024-04-29
2023-12-31 10-K2023-12-312024-02-15
2023-09-30 10-Q2023-09-302023-11-02
2023-06-30 10-Q2023-06-302023-08-03
2023-03-31 10-Q2023-03-312023-05-04
2022-12-31 10-K2022-12-312023-02-28
2022-09-30 10-Q2022-09-302022-11-03
2022-06-30 10-Q2022-06-302022-08-04
2022-03-31 10-Q2022-03-312022-05-10
2021-12-31 10-K2021-12-312022-02-28
2021-09-30 10-Q2021-09-302021-11-03
2021-06-30 10-Q2021-06-302021-08-05
2021-03-31 10-Q2021-03-312021-05-06
2020-12-31 10-K2020-12-312021-04-30
2020-12-31 10-K2020-12-312021-02-24
2019-12-31 40-F2019-12-312020-03-05
2018-12-31 40-F2018-12-312019-03-19
1
2
20 / page
About
Name
Aurinia Pharmaceuticals Inc.
Overview
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Show More
CEO
Mr. Peter S. Greenleaf M.B.A.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2014-09-03
Address
118 Avenue , 14315, Suite 140, Edmonton, AB, T5L 4S6, Canada
Tel
250-744-2487
Website
https://www.auriniapharma.com